Torcetrapib

About Torcetrapib (CAS 262352-17-0)

Torcetrapib, also known as PF-06667560, is a small molecule widely studied as a cholesteryl ester transfer protein (CETP) inhibitor. Identified under CAS 262352-17-0, this compound gained attention in cardiovascular research due to its ability to influence lipid metabolism and high-density lipoprotein levels. Developed within Pfizer torcetrapib programs, it remains an important reference molecule for understanding CETP inhibition and its systemic effects.

Researchers frequently evaluate Torcetrapib chemical structure to understand its interaction with lipid transport mechanisms and CETP binding sites. In parallel, Torcetrapib molecular weight is considered during formulation and assay development, supporting precise experimental design and reproducibility in both biochemical and pharmacological studies.

Application Torcetrapib

Application Torcetrapib is centered on lipid metabolism, cardiovascular biology, and CETP inhibition studies. It is commonly used to explore mechanisms that regulate cholesterol transport and to assess therapeutic strategies targeting dyslipidemia.

• investigation of CETP inhibition and HDL cholesterol modulation
• evaluation of lipid transport pathways in cardiovascular research
• comparative studies with other CETP inhibitors and lipid-lowering strategies

These applications make torcetrapib relevant for both mechanistic research and drug discovery programs focused on metabolic and cardiovascular disorders.

In Vitro

In vitro, torcetrapib demonstrates its activity through inhibition of CETP, which plays a central role in the transfer of cholesteryl esters between lipoproteins. This property allows researchers to assess compound effects in controlled assay systems, including biochemical binding assays and lipid transfer studies.

Such experiments provide insights into potency, selectivity, and interaction dynamics, forming a foundation for further in vivo investigation.

In Vivo

In vivo studies of torcetrapib have shown its capacity to significantly increase HDL cholesterol levels. However, research also revealed complex physiological responses beyond lipid modulation, which contributed to discontinuation of its clinical development. Despite this, torcetrapib Pfizer remains widely used as a model compound to study CETP inhibition and systemic cardiovascular effects.

These findings highlight the importance of comprehensive evaluation in translational research, particularly when targeting multifactorial metabolic pathways.

Biochemical and Physiological Actions

The primary biochemical mechanism of torcetrapib involves inhibition of CETP, leading to altered lipid exchange between lipoprotein particles. This results in increased HDL cholesterol and changes in low-density lipoprotein levels, directly impacting lipid homeostasis.

From a physiological perspective, torcetrapib influences cardiovascular risk markers and lipid profiles, making it a valuable tool for studying cholesterol regulation and drug-target interactions in metabolic pathways.

Features and benefits Torcetrapib

Torcetrapib offers well-documented pharmacological properties and remains relevant for research despite its discontinued clinical use. When provided as EBC-497104, it is supported by analytical validation and quality control standards.

• established reference compound for CETP inhibition studies
• extensive research background in lipid metabolism and cardiovascular science
• applicability in both in vitro and in vivo experimental models

As part of a comprehensive portfolio of bioactive molecules, torcetrapib supports advanced research into lipid regulation and cardiovascular biology, enabling scientists to investigate complex mechanisms with greater clarity and precision.